BusinessActinium Pharmaceuticals Announces Commencement of Rights Offering Subscription PeriodBy Nasdaq OMXFeb 22, 2018, 12:31 PM UTC
BusinessAxiom Real-Time Metrics Showcasing Fusion eClinical Suite at Outsourcing in Clinical Trials West Coast 2018By Nasdaq OMXFeb 20, 2018, 5:01 PM UTC
BusinessActinium Pharmaceuticals Announces Product Showcase and Other Visibility Extending Activities at the BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant OrganizationsBy Nasdaq OMXFeb 20, 2018, 12:30 PM UTC
BusinessActinium Announces Submission of IND For Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AMLBy Nasdaq OMXFeb 12, 2018, 9:15 PM UTC
BusinessActinium Appoints Anil Kapur as Chief Commercial Officer to Build Critical Commercial & Launch Capabilities Focused on MyeloablationBy Nasdaq OMXFeb 8, 2018, 1:01 PM UTC
BusinessActinium Pharmaceuticals Reminds Investors of Record Date for Rights OfferingBy Nasdaq OMXFeb 7, 2018, 2:01 PM UTC
BusinessActinium Pharmaceuticals Announces Trial to Study Actimab-A in Combination with CLAG-M for Relapsed or Refractory AML PatientsBy Nasdaq OMXFeb 6, 2018, 12:30 PM UTC
BusinessActinium Pharmaceuticals Announces Acceptance of Abstract for AACR Annual Meeting Highlighting Superior In Vivo Survival Data for Actinium Labelled Daratumumab Versus Unlabeled Daratumumab, A Blockbuster ProductBy Nasdaq OMXFeb 1, 2018, 12:31 PM UTC
